Lonza Announces Results of the 2017 Annual General Meeting – All Motions Proposed by Board of Directors Accepted



Dirk Oehlers

Head Investor Relations
+41 61 316 8540

Dominik Werner
Head Corporate Communications
+41 61 316 8798

Constance Ward
Head External Communications
+41 61 316 8840

  • 235 shareholders attended, representing 59.96% of the share capital
  • Shareholders re-elected all existing members of the Board of Directors except for Thomas Ebeling, who did not stand for re-election, and approved the new election of Albert M. Baehny
  • Rolf Soiron was re-elected as Board Chairperson for another year
  • A dividend of CHF 2.75 per share will be paid out as from 3 May 2017
BASEL, SWITZERLAND–Today’s Annual General Meeting of Lonza Group Ltd, led by the Chairperson of the Board of Directors, Rolf Soiron, was attended by 235 shareholders. They represented 59.96% of the share capital.
The Board members standing for re-election (Rolf Soiron, Patrick Aebischer, Werner Bauer, Jean-Daniel Gerber, Christoph Mäder, Barbara Richmond, Margot Scheltema, Juergen Steinemann and Antonio Trius) were all elected for a further term in office of one year. Thomas Ebeling did not stand for re-election. The shareholders also elected Albert M. Baehny as a new member of the Board. The Annual General Meeting re-elected Rolf Soiron as Chairperson of the Board of Directors for a further term in office of one year, as well as the three acting members of the Nomination and Compensation Committee.
The shareholders strongly supported all other motions proposed by the Board of Directors, including among others the remuneration report and the binding votes on the compensation for the Board of Directors and the Executive Committee.
A dividend of CHF 2.75 per share, as proposed by the Board of Directors and accepted by the shareholders, will be paid out from 3 May 2017.
The shareholders also supported the increase of the share capital by the issuance of up to 22,000,000 fully paid registered shares to raise gross proceeds in the amount of approximately CHF 2.3 billion by way of a rights offering, the reintroduction of authorized capital in the amount of CHF 7,500,000, and an increase of the existing conditional capital from currently CHF 5,029,860 to CHF 7,500,000.

About Lonza
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.
Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B3 compounds personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 9,800 full-time employees worldwide. The company generated sales of CHF 3.8 billion in 2015 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at

Return Home